IL126095A0 - Azolobenzazepine derivatives as neurogically active agents - Google Patents
Azolobenzazepine derivatives as neurogically active agentsInfo
- Publication number
- IL126095A0 IL126095A0 IL12609597A IL12609597A IL126095A0 IL 126095 A0 IL126095 A0 IL 126095A0 IL 12609597 A IL12609597 A IL 12609597A IL 12609597 A IL12609597 A IL 12609597A IL 126095 A0 IL126095 A0 IL 126095A0
- Authority
- IL
- Israel
- Prior art keywords
- neurogically
- azolobenzazepine
- derivatives
- active agents
- agents
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- PLKKXWBJOVTVEU-UHFFFAOYSA-N pyrrolo[2,3-i][1]benzazepine Chemical class C1=CC=NC2=C3C=CN=C3C=CC2=C1 PLKKXWBJOVTVEU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1352896P | 1996-03-08 | 1996-03-08 | |
| PCT/GB1997/000592 WO1997032883A1 (en) | 1996-03-08 | 1997-03-04 | Azolobenzazepine derivatives as neurologically active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL126095A0 true IL126095A0 (en) | 1999-05-09 |
Family
ID=21760422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12609597A IL126095A0 (en) | 1996-03-08 | 1997-03-04 | Azolobenzazepine derivatives as neurogically active agents |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6124281A (enExample) |
| EP (1) | EP0888350A1 (enExample) |
| JP (1) | JP2000506160A (enExample) |
| KR (1) | KR19990087585A (enExample) |
| CN (1) | CN1084747C (enExample) |
| AU (1) | AU723860B2 (enExample) |
| CA (1) | CA2247453A1 (enExample) |
| IL (1) | IL126095A0 (enExample) |
| NO (1) | NO984106L (enExample) |
| NZ (1) | NZ330973A (enExample) |
| TW (1) | TW486480B (enExample) |
| WO (1) | WO1997032883A1 (enExample) |
| ZA (1) | ZA971964B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100389140B1 (ko) * | 1997-09-29 | 2003-06-25 | 메이지 세이카 가부시키가이샤 | 삼환성 트리아졸로벤즈아제핀 유도체 및 그의 제조방법 및항알레르기제 |
| US7919109B2 (en) * | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| US7002009B2 (en) | 2001-12-26 | 2006-02-21 | Meiji Seika Kaisha, Ltd. | Crystalline tricyclic triazolobenzazepine derivative |
| AU2003212979A1 (en) * | 2002-02-07 | 2003-09-02 | Neurogen Corporation | Substituted fused pyrazolecarboxylic acid arylamides and related compounds |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| HRP20080120T5 (hr) | 2004-05-14 | 2012-07-31 | Millennium@Pharmaceuticals | Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
| EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| CN104000779A (zh) | 2007-04-23 | 2014-08-27 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| WO2010074724A1 (en) | 2008-12-22 | 2010-07-01 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| RU2753280C2 (ru) | 2009-09-28 | 2021-08-12 | Интарсия Терапьютикс, Инк. | Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства |
| RU2012140021A (ru) | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| EP2976086B1 (en) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| WO2016196851A2 (en) | 2015-06-03 | 2016-12-08 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| EP3324976A4 (en) | 2015-07-21 | 2019-03-27 | Millennium Pharmaceuticals, Inc. | ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS |
| JP7077237B2 (ja) | 2016-05-16 | 2022-05-30 | インターシア セラピューティクス，インコーポレイティド | グルカゴン受容体選択的ポリペプチド及びその使用方法 |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9311948D0 (en) * | 1993-06-10 | 1993-07-28 | Zeneca Ltd | Substituted nitrogen heterocycles |
| DE69427023T2 (de) * | 1993-12-28 | 2001-10-31 | Meiji Seika K.K., Tokio/Tokyo | Tricyclische benzazepin-und benzothiazepin derivate |
| WO1997000258A1 (en) * | 1995-06-15 | 1997-01-03 | Meiji Seika Kabushiki Kaisha | Tricyclic benzazepine compounds |
-
1997
- 1997-03-04 TW TW086102601A patent/TW486480B/zh active
- 1997-03-04 AU AU22253/97A patent/AU723860B2/en not_active Ceased
- 1997-03-04 EP EP97905327A patent/EP0888350A1/en not_active Withdrawn
- 1997-03-04 JP JP9531562A patent/JP2000506160A/ja not_active Ceased
- 1997-03-04 US US09/142,221 patent/US6124281A/en not_active Expired - Fee Related
- 1997-03-04 NZ NZ330973A patent/NZ330973A/xx unknown
- 1997-03-04 CA CA002247453A patent/CA2247453A1/en not_active Abandoned
- 1997-03-04 WO PCT/GB1997/000592 patent/WO1997032883A1/en not_active Ceased
- 1997-03-04 IL IL12609597A patent/IL126095A0/xx unknown
- 1997-03-04 CN CN97192864A patent/CN1084747C/zh not_active Expired - Fee Related
- 1997-03-04 KR KR1019980707026A patent/KR19990087585A/ko not_active Withdrawn
- 1997-03-06 ZA ZA9701964A patent/ZA971964B/xx unknown
-
1998
- 1998-09-07 NO NO984106A patent/NO984106L/no not_active Application Discontinuation
-
2000
- 2000-09-22 US US09/668,261 patent/US6313290B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA971964B (en) | 1997-09-08 |
| KR19990087585A (ko) | 1999-12-27 |
| NZ330973A (en) | 2000-03-27 |
| AU723860B2 (en) | 2000-09-07 |
| EP0888350A1 (en) | 1999-01-07 |
| CA2247453A1 (en) | 1997-09-12 |
| US6313290B1 (en) | 2001-11-06 |
| JP2000506160A (ja) | 2000-05-23 |
| NO984106L (no) | 1998-11-06 |
| CN1084747C (zh) | 2002-05-15 |
| CN1224424A (zh) | 1999-07-28 |
| NO984106D0 (no) | 1998-09-07 |
| AU2225397A (en) | 1997-09-22 |
| WO1997032883A1 (en) | 1997-09-12 |
| US6124281A (en) | 2000-09-26 |
| TW486480B (en) | 2002-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL126095A0 (en) | Azolobenzazepine derivatives as neurogically active agents | |
| EG24081A (en) | 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives | |
| GB9510757D0 (en) | Therapeuticaly active compounds | |
| HUP0003642A3 (en) | N-alkanoylphenylalanine derivatives | |
| GB9702194D0 (en) | Sulphonide derivatives | |
| HUP0000575A3 (en) | Novel formulation comprising budesonid as active indegredient | |
| HUP0100870A3 (en) | Alpha-aminoamide derivatives useful as analgesic agents | |
| HUP9801168A3 (en) | Triazinylaminostilbene derivatives | |
| GB2321457B (en) | 5-Aroylnaphthalene derivatives | |
| IL132982A0 (en) | Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives | |
| GB9715821D0 (en) | Amidino-camptothecin derivatives | |
| GB9725541D0 (en) | Amino-benzothiazole derivatives | |
| AU2361295A (en) | N-carboxyalkyl derivatives as antidegenerative active agents | |
| GB9701628D0 (en) | Imino-aza-anthracyclinone derivatives | |
| GB9603431D0 (en) | Immunodulating active substance | |
| EP0910356A4 (en) | BIPHENYLAMIDO DERIVATIVES AS MELATONERGIC AGENTS | |
| ZA983116B (en) | Arylsecocholadiene derivatives | |
| AP9901651A0 (en) | Nitro-benzamide useful as anti-arrhytmic agent | |
| IL131159A0 (en) | 4-Aminoethoxyindazole derivatives | |
| GB9706753D0 (en) | Aralkoxy-morphinan derivatives | |
| SI1005445T1 (en) | N-alkanoylphenylalanine derivatives | |
| GB9608678D0 (en) | Pharmaceuticlly active compounds | |
| PL316604A1 (en) | Active self-extinguising line | |
| GB9709884D0 (en) | Pharmacoligically active compounds | |
| HK1016901A (en) | Biphenylamido derivatives as melatonergic agents |